Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123890 · ClinicalTrials.gov registry record · Phase 3
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00123890 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline.
The verdict
NCT00123890, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
Interventions
- DRUG GW873140
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00123890
The ClinicalTrials.gov registry entry for NCT00123890 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW873140 is the first listed.
NCT00123890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00123890 about?
NCT00123890 is a clinical study titled "Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140". The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
What is the current status of trial NCT00123890?
This trial is currently terminated. It is a Phase 3 study. The study started on 2005-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00123890?
The interventions under investigation include: GW873140 (DRUG).
Who is sponsoring clinical trial NCT00123890?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.